Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LIV1039
- Development stage
- Preclinical
- Lead developer
- Livmor Biosciences
- Modality
- Peptides
01
Overview
LIV1039 is a preclinical-stage combination therapeutic being developed by Livmor Biosciences for the prevention and treatment of preterm premature rupture of membranes (PPROM), preterm birth, fetal inflammation, and newborn sepsis. The drug is a combination of two allosteric receptor peptide antagonists: Rytvela, an allosteric negative modulator of the interleukin-1 receptor (IL-1R) that targets interleukin-1 beta (IL-1β) signaling, and HSJ699 (also referred to as HSJ633), an allosteric antagonist of the interleukin-6 receptor (IL-6R). By inhibiting both IL-1β and IL-6 signaling pathways, LIV1039 aims to suppress the inflammatory cascade that triggers premature labor and fetal/neonatal organ damage, while preserving maternal innate immunity.
- Other names
- Rytvela + HSJ633Rytvela + HSJ699
02
Targets
IL1B (Interleukin-1 beta)IL-1R (Interleukin-1 receptor type 1 (IL-1R1))IL-6 (Interleukin 6)IL-6R (Interleukin-6 receptor subunit alpha)
Beyond the preview
Go deeper on LIV1039.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LIV1039.